| Property | Value |
|---|
|
?:abstract
|
-
To date, there are no studies on COVID-19 specifically dedicated to patients with gastrointestinal cancer. Current data based on small Chinese studies suggest that SARS-CoV-2 infection is 2 to 3 times more common in cancer patients than in the general population and associated with more serious and lethal forms of COVID-19. However, these data need to be confirmed and completed. A French cohort of Cooperative Groups in Oncology, dedicated to cancer patients and COVID-19 (GCO-02 CACOVID-19) and promoted by the FFCD, is currently open to inclusions in an attempt to improve knowledge in this area. While waiting to learn more, the epidemic has led groups of experts and societies to propose recommendations aimed at protecting cancer patients from contamination, limiting situations at risk and organizing in the best conditions the continuation of anti-cancer treatments. In this context, a new chapter of the National Thesaurus of Digestive Oncology dedicated to the management of digestive cancers according to the COVID-19 epidemic situation has been posted on the SNFGE website and is regularly updated.
|
|
is
?:annotates
of
|
|
|
?:creator
|
|
|
?:journal
|
-
Hepato-Gastro_Oncol._Dig.
|
|
?:license
|
|
|
?:publication_isRelatedTo_Disease
|
|
|
is
?:relation_isRelatedTo_publication
of
|
|
|
?:source
|
|
|
?:title
|
-
Management in oncology during COVID-19 epidemic/ Prise en charge en oncologie digestive dans le contexte du COVID-19
|
|
?:type
|
|
|
?:who_covidence_id
|
|
|
?:year
|
|
![[This page as RDF]](https://research.tib.eu/covid-19/static/rdf-icon.gif){kind=icon}